WGS — GeneDx Holdings Corp.

Summary of GeneDx Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $116.7 million, a 52% year-over-year increase.
• Exome and Genome Revenue: $98.9 million, up 66% year-over-year, with 25,702 tests performed.
• Adjusted Gross Margin: 74%, improved due to favorable mix shift and lower cost of goods sold (COGS).
• Adjusted Net Income: $14.7 million, with adjusted basic EPS of $0.51.
• Cash Position: $156 million in cash, cash equivalents, and marketable securities.
• Free Cash Flow: $9 million generated in Q3.

2. Strategic Updates and Business Highlights

• Growth Strategy: GeneDx aims to enhance patient care through early disease diagnosis, leveraging the GeneDx Infinity database, which is the largest rare disease dataset.
• FDA Breakthrough Device Designation: Recently granted for ExomeDx and GenomeDx tests, validating their technology.
• Executive Hires: New Chief Business Officer and Chief Precision Medicine Officer appointed to strengthen partnerships and clinical adoption.
• Sales Force Expansion: Plans to nearly double the sales force to penetrate new markets, particularly general pediatricians.
• NICU Market Focus: Less than 5% of NICU patients currently receive genetic testing; GeneDx is working to increase this through integrations with health systems.
• Newborn Screening Initiatives: Participation in NIH Beacon program and Sunshine Genetics Network to enhance genomic newborn screening capabilities.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to $425 million - $428 million for full-year 2025.
• Exome and Genome Revenue Growth: Expected to grow by 53% - 55%, with a target of $358 million - $361 million.
• Volume Growth: Anticipated to maintain at least 30% for full-year 2025, with expectations of accelerating growth into Q4.
• Adjusted Gross Margin Guidance: Raised to 70% - 71%.

4. Bad News, Challenges, or Points of Concern

• Discontinued Offerings: The hereditary cancer business, which generated $1.2 million in Q3 2025, will be phased out, impacting future revenues.
• Potential ASP Decline: New market expansions may initially result in lower average selling prices (ASP) and reimbursement rates as new accounts are onboarded.
• Operational Expenses: Increased operational expenses (OpEx) to $71 million, representing 61% of revenue, as investments are made for future growth.
• Market Education: Significant effort required to educate general pediatricians about genetic testing, which may delay volume growth in this segment by 18 to 24 months.

5. Notable Q&A Insights

• NICU Contribution: The NICU remains a key growth area, with expectations for increased testing volumes as more health systems adopt GeneDx's solutions.
• Medi-Cal Impact: The expansion of Medi-Cal coverage is expected to significantly improve reimbursement rates, transitioning from zero to approximately 80% for certain tests.
• Long-term Pricing Strategy: GeneDx is focused on demonstrating the value of its innovations to payers to maintain pricing power amid competition.
• Sales Force Development: The company is strategically hiring and training sales personnel to ensure effective market penetration and support for new pediatrician accounts.
• Clinical Adoption Timeline: While there is optimism about the general pediatrician market, skepticism remains regarding the 18 to 24-month timeline for significant volume contributions.

Overall, GeneDx reported strong financial growth and strategic advancements while navigating challenges related to market education and operational scaling. The company remains focused on leveraging its unique data capabilities to drive future growth in the precision medicine landscape.